Agenus (NASDAQ:AGEN) issued its quarterly earnings data on Thursday. The biotechnology company reported ($0.40) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.28) by ($0.12), MarketWatch Earnings reports.
Shares of NASDAQ AGEN opened at $2.99 on Friday. The company has a market cap of $336.00 million, a PE ratio of -2.43 and a beta of 2.09. Agenus has a 12-month low of $1.54 and a 12-month high of $6.02.
Several equities analysts have recently issued reports on AGEN shares. Zacks Investment Research downgraded Agenus from a “hold” rating to a “sell” rating in a research report on Tuesday, January 8th. BidaskClub upgraded Agenus from a “hold” rating to a “buy” rating in a research report on Thursday, January 10th. Finally, ValuEngine upgraded Agenus from a “hold” rating to a “buy” rating in a research report on Thursday, January 17th.
COPYRIGHT VIOLATION WARNING: “Agenus (AGEN) Posts Quarterly Earnings Results, Misses Estimates By $0.12 EPS” was originally reported by Dakota Financial News and is owned by of Dakota Financial News. If you are accessing this story on another domain, it was copied illegally and republished in violation of international trademark and copyright legislation. The legal version of this story can be viewed at https://dakotafinancialnews.com/2019/03/15/agenus-agen-posts-quarterly-earnings-results-misses-estimates-by-0-12-eps.html.
Agenus Inc, a clinical-stage immuno-oncology company, focuses on the discovery and development of therapies that engage the body's immune system to fight cancer. The company offers Retrocyte Display, an antibody discovery platform for the identification of fully-human and humanized monoclonal antibodies; SECANT yeast display, an antibody discovery platform used for the generation of novel monoclonal antibodies; and phage display technologies.
Further Reading: Beta
Receive News & Ratings for Agenus Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Agenus and related companies with MarketBeat.com's FREE daily email newsletter.